RT Journal Article
T1 Profiling Neuroactive Steroid Levels After Traumatic Brain Injury in Male Mice
A1 López Rodríguez, Ana Belén
A1 Acaz Fonseca, Estefanía
A1 Spezzano, Roberto
A1 Giatti, Silvia
A1 Caruso, Donatella
A1 Viveros, María Paz
A1 Melcangi, Roberto C.
A1 García Segura, Luis Miguel
AB The incidence of traumatic brain injuries (TBIs) in humans has rapidly increased in the last ten years. The most common causes are falls and car accidents. Approximately 80 000-90 000 persons per year will suffer some permanent disability as a result of the lesion, and one of the most common symptoms is the decline of hormone levels, also known as post-TBI hormonal deficiency syndrome. This issue has become more and more important, and many studies have focused on shedding some light on it. The hormonal decline affects not only gonadal steroid hormones but also neuroactive steroids, which play an important role in TBI recovery by neuroprotective and neurotrophic actions. The present work used an adolescent close-head murine model to analyze brain and plasma neurosteroid level changes after TBI and to establish correlations with edema and neurological impairments, 2 of the hallmarks of TBI. Our results showed changes in brain pregnenolone, testosterone, dihydrotestosterone (DHT), and 3α-diol levels whereas in plasma, the changes were present in progesterone, DHT, 3α-diol, and 3β-diol. Within them, pregnenolone, progesterone, DHT, and 3α-diol levels positively correlated with edema formation and neurological score, whereas testosterone inversely correlated with these 2 variables. These findings suggest that changes in the brain levels of some neuroactive steroids may contribute to the alterations in brain function caused by the lesion and that plasma levels of some neuroactive steroids could be good candidates of blood markers to predict TBI outcome.
PB Endocrine Society
SN 0013-7227
YR 2016
FD 2016
LK https://hdl.handle.net/20.500.14352/23353
UL https://hdl.handle.net/20.500.14352/23353
LA eng
NO Ministerio de Economía y Competitividad (MINECO)
NO Fondazione Cariplo
DS Docta Complutense
RD 9 abr 2025